ASHP supports the use of niacin as an effective therapy for the management of dyslipidemias in adults. Successful and safe therapy requires ongoing supervision and instruction by qualified health care providers to monitor the efficacy of therapy and minimize niacin's potential for adverse effects. Because many niacin products are available without a prescription, pharmacists are in a unique position to help ensure that patients make the best use of this medication.

 

This article has been cited by other articles:

				A. L Rogovik, S. Vohra, and R. D Goldman Safety Considerations and Potential Interactions of Vitamins: Should Vitamins Be Considered Drugs? Ann. Pharmacother., February 1, 2010; 44(2): 311 - 324. [Abstract] [Full Text] [PDF]

				I. O. Poon, D. S.-L. Chow, and D. Liang Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2128 - 2134. [Abstract] [Full Text] [PDF]

				A. Joseph, T. Kothari, and S. Venkatesh Niacin toxicity: a rare presentation mimicking malignancy. Age Ageing, July 1, 2006; 35(4): 448 - 448. [Full Text] [PDF]

				S. Sahni, C. A. Hepfinger, and K. A. Sauer Guggulipid use in hyperlipidemia: Case report and review of the literature Am. J. Health Syst. Pharm., August 15, 2005; 62(16): 1690 - 1692. [Full Text] [PDF]

				J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]

				M. Miller Niacin as a Component of Combination Therapy for Dyslipidemia Mayo Clin. Proc., June 1, 2003; 78(6): 735 - 742. [Abstract] [PDF]